Lipid-based nanocarriers for antifungal drug delivery
Source abstract
Abstract
Fungal diseases constitute a rapidly escalating global health threat, causing an estimated 1.5-2 million deaths annually and affecting more than one billion individuals worldwide, particularly immunocompromised patient populations. The increasing incidence of severe systemic infections, severely limited therapeutic options, prolonged treatment regimens, and the rapid emergence of antimycotic resistance collectively underscore the urgent clinical need for innovative treatment strategies. Consequently, the World Health Organization (WHO) has highlighted sustainable investment in antifungal research and the targeted development of novel therapeutics as a primary global priority. Nanotechnology-based drug delivery systems, particularly advanced lipid-based nanocarriers, offer highly promising solutions to overcome current therapeutic limitations. Sophisticated vesicular systems have successfully demonstrated improved target-site accumulation, highly controlled drug release, enhanced tissue penetration (including deep ocular and cutaneous applications), and drastically reduced systemic toxicity in both preclinical and selected clinical settings. Furthermore, PEGylated and ligand-functionalized liposomes, such as DC-SIGN targeted amphotericin B formulations, significantly improve pathogen-specific binding and overall antifungal activity in rigorous experimental models. Emerging formulation strategies, including pH-responsive stealth liposomes and stimuli-sensitive systems adapted directly from oncological applications, suggest immense potential for maximizing antifungal selectivity and clinical efficacy. Additionally, advanced liposome-in-hydrogel hybrid matrices enable sustained therapeutic release, remarkably enhancing formulation stability while minimizing off-target systemic exposure. This comprehensive review provides an integrative analysis of nanostructured lipid carriers in antifungal therapy, detailing fundamental mechanistic principles, advanced formulation strategies, scalable preparation methodologies, and diverse clinical applications. Particular emphasis is strategically placed on highly deformable liposomal platforms explicitly engineered to overcome the structural limitations of conventional delivery systems. Ultimately, successfully bridging the formidable translational gap between experimental benchtop innovation and routine clinical implementation requires harmonized regulatory frameworks, scalable and reproducible manufacturing protocols, rigorous quality control, and substantially enhanced public and private sector collaboration. By synthesizing mechanistic pharmacological insights with realistic translational and regulatory perspectives, this work aims to advance the fundamental understanding of lipid-based antifungal delivery platforms and directly support the development of highly effective, clinically viable therapeutic approaches.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Polydiacetylene-based materials and applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Abd-Elmonem EM, Makky AM, Khalil IA, Abd-Elsalam WH. Nanoformulations of antifungal agents for the management of ocular fungal infections. BioNanoScience. 2025. https://doi.org/10.1007/s12668-025-02032-z.10.1007/s12668-025-02032-z ↗
2. Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: in-vitro, ex-vivo and in-vivo evaluation. Int J Pharm. 2017;527(1–2):1–11. https://doi.org/10.1016/j.ijpharm.2017.05.029.10.1016/j.ijpharm.2017.05.029 ↗
3. Abdulbaqi IM, Darwis Y, Abou Assi R, Abdul Karim Khan N. Transethosomal gels as carriers for the transdermal delivery of colchicine: statistical optimization, characterization, and ex vivo evaluation. Drug Des Devel Ther. 2018;12:795–813. https://doi.org/10.2147/dddt.s158018.10.2147/dddt.s158018 ↗
4. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002;49(suppl_1):21–30.10.1093/jac/49.suppl_1.21 ↗
5. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14:25–36. https://doi.org/10.1111/j.1469-0691.2008.01979.x.10.1111/j.1469-0691.2008.01979.x ↗
6. Ahmed TA, Alzahrani MM, Sirwi A, Alhakamy NA. Study the antifungal and ocular permeation of ketoconazole from ophthalmic formulations containing trans-ethosomes nanoparticles. Pharmaceutics. 2021;13(2):151. https://doi.org/10.3390/pharmaceutics13020151.10.3390/pharmaceutics13020151 ↗
7. Ahonkhai V, Martins SF, Portet A, Lumpkin M, Hartman D. Speeding access to vaccines and medicines in low- and middle-income countries: a case for change and a framework for optimized product market authorization. PLoS ONE. 2016;11(11):e0166515. https://doi.org/10.1371/journal.pone.0166515.10.1371/journal.pone.0166515 ↗
8. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. https://doi.org/10.1186/1556-276x-8-102.10.1186/1556-276x-8-102 ↗
9. Albash R, Elmahboub Y, Baraka K, Abdellatif MM, Alaa-Eldin AA. Ultra-deformable liposomes containing terpenes (terpesomes) loaded fenticonazole nitrate for treatment of vaginal candidiasis: Box-Behnken design optimization, comparative ex vivo and in vivo studies. Drug Deliv. 2020;27(1):1514–23. https://doi.org/10.1080/10717544.2020.1837295.10.1080/10717544.2020.1837295 ↗
10. Albash R, Ragaie MH, Hassab MAE, El-Haggar R, Eldehna WM, Al-Rashood ST, et al. Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis: design characterization, in silico study, and exploratory clinical appraisal. Drug Deliv. 2022;29(1):1100–11. https://doi.org/10.1080/10717544.2022.2057619.10.1080/10717544.2022.2057619 ↗
11. Aldahasi RM, Alghamdi SS, Albulushi N, Alhuraibi H, Suliman RS, Alsubait A, et al. Metabolite detection via QTOF-LCMS and computational analysis on Russelia equisetiformis exploring green nanotechnology and antifungal against phytopathogens. Chem Biol Technol Agric. 2025. https://doi.org/10.1186/s40538-025-00850-7.10.1186/s40538-025-00850-7 ↗
12. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. https://doi.org/10.1016/j.addr.2012.09.037.10.1016/j.addr.2012.09.037 ↗
13. Alyahya EM, Alwabsi K, Aljohani AE, Albalawi R, El-Sherbiny M, Ahmed R, et al. Preparation and optimization of itraconazole transferosomes-loaded HPMC hydrogel for enhancing its antifungal activity: 2^3 full factorial design. Polymers Basel. 2023;15(4):995. https://doi.org/10.3390/polym15040995.10.3390/polym15040995 ↗
14. Ambati S, Pham T, Lewis ZA, Lin X, Meagher RB. DC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi. Fungal Biol Biotechnol. 2021;8:22. https://doi.org/10.1186/s40694-021-00126-3.10.1186/s40694-021-00126-3 ↗
15. Asadi P, Mehravaran A, Soltanloo N, Abastabar M, Akhtari J. Nanoliposome-loaded antifungal drugs for dermal administration: a review. Curr Med Mycol. 2021;7(1):71–8. https://doi.org/10.18502/cmm.7.1.6247.10.18502/cmm.7.1.6247 ↗
16. Ascenso A, Batista C, Cardoso P, Mendes T, Praça F, Bentley V, et al. Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes. Int J Nanomed. 2015;10:5837–51. https://doi.org/10.2147/ijn.s86186.10.2147/ijn.s86186 ↗
17. Atre P, Rizvi SAA. A brief overview of quality by design approach for developing pharmaceutical liposomes as nano-sized parenteral drug delivery systems. RSC Pharm. 2024;1:675–88.10.1039/D4PM00201F ↗
18. Bachhav YG, Mondon K, Kalia YN, Gurny R, Möller M. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Control Release. 2011;153(2):126–32. https://doi.org/10.1016/j.jconrel.2011.03.003.10.1016/j.jconrel.2011.03.003 ↗
19. Bajwa M, Tabassam N, Hameed H, Irfan A, Zaman M, Khan MA, et al. Thermo-responsive sol-gel-based nano-carriers containing terbinafine HCl: formulation, in vitro and ex vivo characterization, and antifungal activity. Gels. 2023;9(10):830. https://doi.org/10.3390/gels9100830.10.3390/gels9100830 ↗
20. Bandara HMHN, Hewavitharana AK, Shaw PN, Smyth HDC, Samaranayake LP. A novel, quorum sensor-infused liposomal drug delivery system suppresses Candida albicans biofilms. Int J Pharm. 2020;578:119096. https://doi.org/10.1016/j.ijpharm.2020.119096.10.1016/j.ijpharm.2020.119096 ↗
21. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–52. https://doi.org/10.1016/s0022-2836(65)80093-6.10.1016/s0022-2836(65)80093-6 ↗
22. Barenholz Y, Peer D. Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. J Control Release. 2012;160(2):115–6. https://doi.org/10.1016/j.jconrel.2012.03.025.10.1016/j.jconrel.2012.03.025 ↗
23. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol. 2009;47(5):368–75.
24. Bhattacharya S. Preparation and characterizations of glyceryl oleate ufasomes of terbinafine hydrochloride: a novel approach to trigger Candida albicans fungal infection. Future J Pharm Sci. 2021;7(1):1–11. https://doi.org/10.1186/s43094-020-00143-w.10.1186/s43094-020-00143-w ↗
25. Bolla PK, Meraz CA, Rodriguez VA, Deaguero I, Singh M, Yellepeddi VK, et al. Clotrimazole loaded ufosomes for topical delivery: formulation development and in-vitro studies. Molecules. 2019;24(17):3139. https://doi.org/10.3390/molecules24173139.10.3390/molecules24173139 ↗
26. Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):57. https://doi.org/10.3390/jof3040057.10.3390/jof3040057 ↗
27. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–99. https://doi.org/10.2147/IJN.S68861.10.2147/IJN.S68861 ↗
28. Braido B, Rukavina Z, Grimstad Ø, Franzè S, Cilurzo F, Vanić Ž, et al. Liposomes-in-hydrogel for topical drug delivery: mechanical, kinetic, and biological insights. J Drug Deliv Sci Technol. 2025;113:107380. https://doi.org/10.1016/j.jddst.2025.107380.10.1016/j.jddst.2025.107380 ↗
29. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13. https://doi.org/10.1126/scitranslmed.3004404.10.1126/scitranslmed.3004404 ↗
30. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. https://doi.org/10.3390/pharmaceutics9020012.10.3390/pharmaceutics9020012 ↗
31. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst. 1996;13(3–4):257–388. https://doi.org/10.1615/critrevtherdrugcarriersyst.v13.i3-4.30.10.1615/critrevtherdrugcarriersyst.v13.i3-4.30 ↗
32. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev. 2004;56(5):675–711. https://doi.org/10.1016/j.addr.2003.10.028.10.1016/j.addr.2003.10.028 ↗
33. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1992;1104(1):226–32. https://doi.org/10.1016/0005-2736(92)90154-e.10.1016/0005-2736(92)90154-e ↗
34. Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers. Transfersomes Biochim Biophys Acta. 2001;1514(2):191–205. https://doi.org/10.1016/s0005-2736(01)00369-8.10.1016/s0005-2736(01)00369-8 ↗
35. Cevc G, Gebauer D. Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. Biophys J. 2003;84(2):1010–24. https://doi.org/10.1016/s0006-3495(03)74917-0.10.1016/s0006-3495(03)74917-0 ↗
36. Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented: evidence from double label CLSM experiments and direct size measurements. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2002;1564(1):21–30. https://doi.org/10.1016/s0005-2736(02)00401-7.10.1016/s0005-2736(02)00401-7 ↗
37. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev. 2004;56(5):675–711.10.1016/j.addr.2003.10.028 ↗
38. Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release. 2010;141(3):277–99. https://doi.org/10.1016/j.jconrel.2009.10.016.10.1016/j.jconrel.2009.10.016 ↗
39. Chandrasekar P. Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Ther Clin Risk Manag. 2008;4(6):1285–94. https://doi.org/10.2147/tcrm.s1554.10.2147/tcrm.s1554 ↗
40. Chaudhari D, Katari O, Ghadi R, Kuche K, Date T, Bhargavi N, et al. Unfolding the potency of adenosine in targeting triple negative breast cancer via paclitaxel-incorporated pH-responsive stealth liposomes. ACS Biomater Sci Eng. 2022;8(8):3473–84. https://doi.org/10.1021/acsbiomaterials.2c00594.10.1021/acsbiomaterials.2c00594 ↗
41. Chen ZX, Li B, Liu T, Wang X, Zhu Y, Wang L, et al. Evaluation of paeonol-loaded transethosomes as transdermal delivery carriers. Eur J Pharm Sci. 2017;99:240–5. https://doi.org/10.1016/j.ejps.2016.12.026.10.1016/j.ejps.2016.12.026 ↗
42. Chen J, Hu S, Sun M, Shi J, Zhang H, Yu H, et al. Recent advances and clinical translation of liposomal delivery systems in cancer therapy. Eur J Pharm Sci. 2024;193:106688. https://doi.org/10.1016/j.ejps.2023.106688.10.1016/j.ejps.2023.106688 ↗
43. Choi W, Kohane DS. Hybrid nanoparticle-hydrogel systems for drug delivery depots and other biomedical applications. ACS Nano. 2024;18(34):22780–92. https://doi.org/10.1021/acsnano.4c06888.10.1021/acsnano.4c06888 ↗
44. Choudhury A, Kirti A, Lenka SS, Naser SS, Sinha A, Kumari S, et al. Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis. J Nanobiotechnol. 2025. https://doi.org/10.1186/s12951-025-03660-z.10.1186/s12951-025-03660-z ↗
45. Chouhan SS, Farooqui N, Mishra DK. Formulation and evaluation of liposomal loaded nail lacquer containing luliconazole an antifungal drug. Asian J Pharm Pharmacol. 2021;7(3):131–7. https://doi.org/10.31024/ajpp.2021.7.3.4.10.31024/ajpp.2021.7.3.4 ↗
46. Corrêa-Junior D, Frases S, de S. Araújo GR. Drug interactions of antifungal agents: clinical relevance and implications. Curr Trop Med Rep. 2025. https://doi.org/10.1007/s40475-024-00336-w.10.1007/s40475-024-00336-w ↗
47. Costa-Barbosa A, Pacheco M, Carneiro C, Botelho CM, Gomes AC, Oliveira ME, et al. Design of a lipid nano-delivery system containing recombinant Candida albicans chitinase 3 as a potential vaccine against fungal infections. Biomed Pharmacother. 2023;66:115362. https://doi.org/10.1016/j.biopha.2023.115362.10.1016/j.biopha.2023.115362 ↗
48. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467–75. https://doi.org/10.1016/j.ymthe.2017.03.013.10.1016/j.ymthe.2017.03.013 ↗
49. Dave V, Sharma S, Yadav RB, Agarwal U. Herbal liposome for the topical delivery of ketoconazole for the effective treatment of seborrheic dermatitis. Appl Nanosci. 2017;7(8):973–87. https://doi.org/10.1007/s13204-017-0634-3.10.1007/s13204-017-0634-3 ↗
50. de Oliveira Kocerginsky P, dos Santos Soares PH, Lyra HFS, Cadena PG, de Lima-Neto RG, Pontes-Filho NT, et al. Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. Braz J Microbiol. 2023;54(3):1513–21. https://doi.org/10.1007/s42770-023-01071-6.10.1007/s42770-023-01071-6 ↗
51. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95. https://doi.org/10.1208/s12248-012-9339-4.10.1208/s12248-012-9339-4 ↗
52. Di T, Zhai C, Zhao J, Wang Y, Chen Z, Li P. Taxifolin inhibits keratinocyte proliferation and ameliorates imiquimod-induced psoriasis-like mouse model via regulating cytoplasmic phospholipase A2 and PPAR-γ pathway. Int Immunopharmacol. 2021;99:107900. https://doi.org/10.1016/j.intimp.2021.107900.10.1016/j.intimp.2021.107900 ↗
53. Dragicevic-Curic N, Gräfe S, Albrecht V, Fahr A. Topical application of temoporfin-loaded invasomes for photodynamic therapy of subcutaneously implanted tumours in mice: a pilot study. J Photochem Photobiol B. 2008;91(1):41–50. https://doi.org/10.1016/j.jphotobiol.2008.01.009.10.1016/j.jphotobiol.2008.01.009 ↗
54. Duangjit S, Obata Y, Sano H, Kikuchi S, Onuki Y, Opanasopit P, et al. Menthosomes, novel ultradeformable vesicles for transdermal drug delivery: optimization and characterization. Biol Pharm Bull. 2012;35(10):1720–8. https://doi.org/10.1248/bpb.b12-00343.10.1248/bpb.b12-00343 ↗
55. Duangjit S, Obata Y, Sano H, Onuki Y, Opanasopit P, Ngawhirunpat T, et al. Comparative study of novel ultradeformable liposomes: menthosomes, transfersomes and liposomes for enhancing skin permeation of meloxicam. Biol Pharm Bull. 2014;37(2):239–47. https://doi.org/10.1248/bpb.b13-00576.10.1248/bpb.b13-00576 ↗
56. Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. Characterization and in vitro skin permeation of meloxicam-loaded liposomes versus transfersomes. J Drug Deliv. 2011;2011:1–9. https://doi.org/10.1155/2011/418316.10.1155/2011/418316 ↗
57. El-Ridy MS, Abdelbary A, Essam T, Abd EL-Salam RM, Aly Kassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm. 2011;37(12):1491–508. https://doi.org/10.3109/03639045.2011.587431.10.3109/03639045.2011.587431 ↗
58. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322(1–2):60–6. https://doi.org/10.1016/j.ijpharm.2006.05.027.10.1016/j.ijpharm.2006.05.027 ↗
59. European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of hypertension. EMA/CHMP/29947/2013/Rev.4; 2013.
60. European Medicines Agency (EMA). Guideline on bioanalytical method validation. London: EMA; 2009.
61. Farhan M. The promising role of polyphenols in skin disorders. Molecules. 2024;29(4):865. https://doi.org/10.3390/molecules29040865.10.3390/molecules29040865 ↗
62. Fazel M, Daeihamed M, Osouli M, Almasi A, Haeri A, Dadashzadeh S. Preparation, in-vitro characterization and pharmacokinetic evaluation of Brij decorated doxorubicin liposomes as a potential nanocarrier for cancer therapy. Iran J Pharm Res. 2018;17(Suppl 2):33–45.
63. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739–42. https://doi.org/10.1126/science.aap7999.10.1126/science.aap7999 ↗
64. Fortune A, Aime A, Raymond D, Kumar S. Nanotechnology in medicine: a double-edged sword for health outcomes. Health Nanotechnology. 2025;1:9. https://doi.org/10.1186/s44301-025-00008-2.10.1186/s44301-025-00008-2 ↗
65. Franz TJ. Percutaneous absorption: on the relevance of in vitro data. J Invest Dermatol. 1975;64(3):190–5. https://doi.org/10.1111/1523-1747.ep12533356.10.1111/1523-1747.ep12533356 ↗
66. Fu Y, Ge Y, Yi S, Peng Q, Jiang H, Zhou J. Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability. J Mater Sci Mater Med. 2026. https://doi.org/10.1007/s10856-026-07012-7.10.1007/s10856-026-07012-7 ↗
67. Garg V, Singh H, Bhatia A, Raza K, Singh SK, Singh B, et al. Systematic development of transethosomal gel system of piroxicam: formulation optimization, in vitro evaluation, and ex vivo assessment. AAPS PharmSciTech. 2016;18(1):58–71. https://doi.org/10.1208/s12249-016-0489-z.10.1208/s12249-016-0489-z ↗
68. Giannella M, Ercolani G, Cristini F, Morelli M, Bartoletti M, Bertuzzo V, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis in patients undergoing liver transplantation. Transplantation. 2015;99(4):848–54. https://doi.org/10.1097/tp.0000000000000393.10.1097/tp.0000000000000393 ↗
69. Güngör S, Erdal MS, Aksu B. New formulation strategies in topical antifungal therapy. J Cosmet Dermatol Sci Appl. 2013;3(1):56–65. https://doi.org/10.4236/jcdsa.2013.31a009.10.4236/jcdsa.2013.31a009 ↗
70. Guo F, Wang J, Ma M, Tan F, Li N. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med. 2015. https://doi.org/10.1007/s10856-015-5487-2.10.1007/s10856-015-5487-2 ↗
71. Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res. 2010;20(4):341–50. https://doi.org/10.3109/08982101003596125.10.3109/08982101003596125 ↗
72. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes--a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm. 2003;29(9):1013–26. https://doi.org/10.1081/ddc-120025458.10.1081/ddc-120025458 ↗
73. Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol. 2009;88(8):901–4. https://doi.org/10.1111/j.1755-3768.2009.01584.x.10.1111/j.1755-3768.2009.01584.x ↗
74. Hameed H, Faheem S, Paiva-Santos AC, Sarwar HS, Jamshaid M. A comprehensive review of hydrogel-based drug delivery systems: Classification, properties, recent trends, and applications. AAPS PharmSciTech. 2024. https://doi.org/10.1208/s12249-024-02786-x.10.1208/s12249-024-02786-x ↗
75. Hashem SM, Gad MK, Anwar HM, Saleh NM, Shamma RN, Elsherif NI. Itraconazole-loaded ufasomes: evaluation, characterization, and anti-fungal activity against Candida albicans. Pharmaceutics. 2023;15(1):26. https://doi.org/10.3390/pharmaceutics15010026.10.3390/pharmaceutics15010026 ↗
76. Hedayati N, Montazer M, Mahmoudirad M, Toliyat T. Ketoconazole and ketoconazole/β-cyclodextrin performance on cotton wound dressing as fungal skin treatment. Carbohydr Polym. 2020;240:116267. https://doi.org/10.1016/j.carbpol.2020.116267.10.1016/j.carbpol.2020.116267 ↗
77. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol. 2005;2(1):67–74. https://doi.org/10.1016/j.ddtec.2005.05.003.10.1016/j.ddtec.2005.05.003 ↗
78. Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143. https://doi.org/10.3389/fphar.2013.00143.10.3389/fphar.2013.00143 ↗
79. Hussain A, Singh S, Sharma D, Webster T, Shafaat K, Faruk A. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine. 2017;12:5087–108. https://doi.org/10.2147/ijn.s138267.10.2147/ijn.s138267 ↗
80. Iizhar SA, Syed IA, Satar R, Ansari SA. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride. J Adv Res. 2016;7(3):453–61. https://doi.org/10.1016/j.jare.2016.03.003.10.1016/j.jare.2016.03.003 ↗
81. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm. 2003;29(9):1013–26. https://doi.org/10.1081/ddc-120025458.10.1081/ddc-120025458 ↗
82. Kamble MG, Singh A, Singh SV, Kamble MG, Sagar NA, Rani N. Nanotechnology for encapsulation of bioactive components: a review. Discover Food. 2025. https://doi.org/10.1007/s44187-025-00386-7.10.1007/s44187-025-00386-7 ↗
83. Kaur C, Maurya P. Antifungal activity of amphotericin-B ethosomal gel against Candida albicans: a comparative study. Int J Pharm Sci Res. 2020;11(1):413–9. https://doi.org/10.13040/ijpsr.0975-8232.11(1).413-19.10.13040/ijpsr.0975-8232.11(1).413-19 ↗
84. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1–14. https://doi.org/10.1016/j.ijpharm.2003.09.016.10.1016/j.ijpharm.2003.09.016 ↗
85. Khan AA, Allemailem KS, Almatroodi SA, et al. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 2020;10:163. https://doi.org/10.1007/s13205-020-2144-3.10.1007/s13205-020-2144-3 ↗
86. Korting HC, Klövekorn W, Klövekorn G. Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole cream 1% in tinea pedis. Clin Drug Investig. 1997;14(4):286–93. https://doi.org/10.2165/00044011-199714040-00006.10.2165/00044011-199714040-00006 ↗
87. Kumar B, Sahoo P. Potential of ethosomes for enhanced transdermal drug delivery in skin diseases. Nanomed J. 2022. https://doi.org/10.22038/nmj.2022.66753.1703.10.22038/nmj.2022.66753.1703 ↗
88. Kumar P, Singh S, Handa V, Kathuria H. Oleic acid nanovesicles of minoxidil for enhanced follicular delivery. Medicines Basel. 2018;5(3):103. https://doi.org/10.3390/medicines5030103.10.3390/medicines5030103 ↗
89. Lane ME. Skin penetration enhancers. Int J Pharm. 2013;447(1–2):12–21. https://doi.org/10.1016/j.ijpharm.2013.02.040.10.1016/j.ijpharm.2013.02.040 ↗
90. Lasic DD. Liposomes: from physics to applications. Elsevier; 1993.
91. Limsuwan T, Amnuaikit T. Development of ethosomes containing mycophenolic acid. Procedia Chem. 2012;4:328–35. https://doi.org/10.1016/j.proche.2012.06.046.10.1016/j.proche.2012.06.046 ↗
92. Ma Y, Cen W, Duan M, Yang J, Wang Y, Gao L, et al. Patients knowledge attitudes and practices regarding superficial fungal infections suggest public health and patient education are warranted. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-98919-8.10.1038/s41598-025-98919-8 ↗
93. Mahapatra M, Mohapatra S, Jena GK. Nanostructured lipid carriers: a revolutionary approach in antifungal drug delivery. Biomed Mater Devices. 2026;4:189–205. https://doi.org/10.1007/s44174-025-00277-6.10.1007/s44174-025-00277-6 ↗
94. Maheshwari RGS, Tekade RK, Sharma PA, Darwhekar G, Tyagi A, Patel RP, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J. 2012;20(2):161–70. https://doi.org/10.1016/j.jsps.2011.10.001.10.1016/j.jsps.2011.10.001 ↗
95. Medhi J, Thalluri C, Vasam M, Bukke SPN. The future of vesicular drug delivery: Transferosomes in therapeutic advancement—applications, innovations and challenges. BioMed Eng OnLine. 2026. https://doi.org/10.1186/s12938-025-01490-6.10.1186/s12938-025-01490-6 ↗
96. Meghana G, Karri VVSR, Talluri SV, Gunda R, Chennareddy S, Ganesh G. Formulation and evaluation of tolnaftate loaded topical liposomal gel for effective skin drug delivery to treat fungal diseases. J Chem Pharm Res. 2014;6(5):856.
97. Mehendiratta H, Singh S, Sharma N, Kishore L, Dwivedi M, Rani A. Advances in liposomes-based-therapeutics as cutting-edge for ocular fungal infections: an updated review. BioNanoScience. 2024;14(3):3522–35. https://doi.org/10.1007/s12668-024-01447-4.10.1007/s12668-024-01447-4 ↗
98. Michelon M, Oliveira DRB, de Figueiredo Furtado G, Gaziola de la Torre L, Cunha RL. High-throughput continuous production of liposomes using hydrodynamic flow-focusing microfluidic devices. Colloids Surf B Biointerfaces. 2017;156:349–57. https://doi.org/10.1016/j.colsurfb.2017.05.033.10.1016/j.colsurfb.2017.05.033 ↗
99. Mosallam S, Albash R, Abdelbari MA. Advanced vesicular systems for antifungal drug delivery. AAPS PharmSciTech. 2022;23:206. https://doi.org/10.1208/s12249-022-02357-y.10.1208/s12249-022-02357-y ↗
100. Mozafari MR, Johnson C, Hatziantoniou S, Demetzos C. Nanoliposomes and their applications in food nanotechnology. J Liposome Res. 2008;18(4):309–27. https://doi.org/10.1080/08982100802465941.10.1080/08982100802465941 ↗